Dr. Agarwal shares LITESPARK-013 results: Optimal dose of belzutifan is 120mg

In this podcast, Dr. Neeraj Agarwal (US), presidential endowed chair of cancer research at the Huntsman Cancer Institute, University of Utah, shares the results of the LITESPARK-013 Phase 2 trial - "Safety and efficacy of two doses of belzutifan in patients with advanced renal cell carcinoma", that he presented at ESMO 2023. Firstly, Dr. Agarwal shares the rationale of the study, which compared belzutifan 200mg and 120mg doses in patients with advanced clear cell RCC that progressed on...